Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 76 to 100 of 761

TitleReference numberPublishedLast updated
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentTA333
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732
Baricitinib for moderate to severe rheumatoid arthritisTA466
Baricitinib for treating moderate to severe atopic dermatitisTA681
Baricitinib for treating severe alopecia areataTA926
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)TA206
Benralizumab for treating severe eosinophilic asthmaTA565
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaTA178
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)TA148
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285

Results per page

  1. 10
  2. 25
  3. 50
  4. All